Midiane Correia Gomes, Emanuelly Karla Araújo Padilha, Gustavo Rafael Angelo Diniz, Edilma Correia Gomes, Paulo Fernando da Silva Santos-Júnior, Peng Zhan, Edeildo Ferreira da Siva-Júnior
{"title":"针对锥虫寄生虫和结核分枝杆菌的多靶点化合物。","authors":"Midiane Correia Gomes, Emanuelly Karla Araújo Padilha, Gustavo Rafael Angelo Diniz, Edilma Correia Gomes, Paulo Fernando da Silva Santos-Júnior, Peng Zhan, Edeildo Ferreira da Siva-Júnior","doi":"10.2174/0113894501306843240606114854","DOIUrl":null,"url":null,"abstract":"<p><p>Multi-target drug treatment has become popular as a substitute for traditional monotherapy. Monotherapy can lead to resistance and side effects. Multi-target drug discovery is gaining importance as data on bioactivity becomes more abundant. The design of multi-target drugs is expected to be an important development in the pharmaceutical industry in the near future. This review presents multi-target compounds against trypanosomatid parasites (<i>Trypanosoma cruzi, T. brucei, and Leishmania sp.</i>) and tuberculosis (<i>Mycobacterium tuberculosis</i>), which mainly affect populations in socioeconomically unfavorable conditions. The article analyzes the studies, including their chemical structures, viral strains, and molecular docking studies, when available. The objective of this review is to establish a foundation for designing new multi-target inhibitors for these diseases.</p>","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":" ","pages":"602-619"},"PeriodicalIF":3.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Multi-target Compounds against Trypanosomatid Parasites and <i>Mycobacterium tuberculosis</i>.\",\"authors\":\"Midiane Correia Gomes, Emanuelly Karla Araújo Padilha, Gustavo Rafael Angelo Diniz, Edilma Correia Gomes, Paulo Fernando da Silva Santos-Júnior, Peng Zhan, Edeildo Ferreira da Siva-Júnior\",\"doi\":\"10.2174/0113894501306843240606114854\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Multi-target drug treatment has become popular as a substitute for traditional monotherapy. Monotherapy can lead to resistance and side effects. Multi-target drug discovery is gaining importance as data on bioactivity becomes more abundant. The design of multi-target drugs is expected to be an important development in the pharmaceutical industry in the near future. This review presents multi-target compounds against trypanosomatid parasites (<i>Trypanosoma cruzi, T. brucei, and Leishmania sp.</i>) and tuberculosis (<i>Mycobacterium tuberculosis</i>), which mainly affect populations in socioeconomically unfavorable conditions. The article analyzes the studies, including their chemical structures, viral strains, and molecular docking studies, when available. The objective of this review is to establish a foundation for designing new multi-target inhibitors for these diseases.</p>\",\"PeriodicalId\":10805,\"journal\":{\"name\":\"Current drug targets\",\"volume\":\" \",\"pages\":\"602-619\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current drug targets\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2174/0113894501306843240606114854\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113894501306843240606114854","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Multi-target Compounds against Trypanosomatid Parasites and Mycobacterium tuberculosis.
Multi-target drug treatment has become popular as a substitute for traditional monotherapy. Monotherapy can lead to resistance and side effects. Multi-target drug discovery is gaining importance as data on bioactivity becomes more abundant. The design of multi-target drugs is expected to be an important development in the pharmaceutical industry in the near future. This review presents multi-target compounds against trypanosomatid parasites (Trypanosoma cruzi, T. brucei, and Leishmania sp.) and tuberculosis (Mycobacterium tuberculosis), which mainly affect populations in socioeconomically unfavorable conditions. The article analyzes the studies, including their chemical structures, viral strains, and molecular docking studies, when available. The objective of this review is to establish a foundation for designing new multi-target inhibitors for these diseases.
期刊介绍：
Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes.
Current Drug Targets publishes guest edited thematic issues written by leaders in the field covering a range of current topics of drug targets. The journal also accepts for publication mini- & full-length review articles and drug clinical trial studies.
As the discovery, identification, characterization and validation of novel human drug targets for drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
